Significance of Fas and FasL protein expression in cardiac carcinoma and local lymph node tissues

International Journal of Clinical and Experimental Pathology

Volumn 8, Issue 9, 2015, Pages 11915-11920

  Li, Yin ^a   Xu, Da Fu ^b,c   Jiang, Dong ^b   Zhao, Jun ^b   Ge, Jin Feng ^b   Zheng, Shi Ying ^b  

^a Department of Thoracic Surgery   (China)

^b THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^c THE AFFILIATED HUAIAN NO 1 PEOPLE S HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Cardiac carcinoma; Fas; Fas ligand FasL; Lymph nodes

Indexed keywords

FAS ANTIGEN; FAS LIGAND; FAS PROTEIN, HUMAN; FASLG PROTEIN, HUMAN; TUMOR MARKER;

ADENOCARCINOMA; ADULT; CARDIA; CASE CONTROL STUDY; CELL DIFFERENTIATION; CHEMISTRY; CHI SQUARE DISTRIBUTION; COMPARATIVE STUDY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE; LYMPH NODE METASTASIS; MALE; MIDDLE AGED; NONLINEAR SYSTEM; PATHOLOGY; SECONDARY; STOMACH TUMOR; YOUNG ADULT;

ADENOCARCINOMA; ADULT; ANTIGENS, CD95; BIOMARKERS, TUMOR; CARDIA; CASE-CONTROL STUDIES; CELL DIFFERENTIATION; CHI-SQUARE DISTRIBUTION; FAS LIGAND PROTEIN; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NONLINEAR DYNAMICS; STOMACH NEOPLASMS; YOUNG ADULT;

EID: 85013350311     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Kase S, Osaki M, Adachi H, Kaibara N and Ito H. Expression of Fas and Fas ligand in esophageal tissue mucosa and carcinomas. Int J Oncol 2002; 20: 291-297.
2. O'Connell J, Bennett MW, O'Sullivan GC, Collins JK and Shanahan F. Resistance to Fas (APO-1/CD95)-mediated apoptosis and expression of Fas ligand in esophageal cancer: the Fas counterattack. Dis Esophagus 1999; 12: 83-89.
3. Shibakita M, Tachibana M, Dhar DK, Kotoh T, Kinugasa S, Kubota H, Masunaga R and Nagasue N. Prognostic significance of Fas and Fas ligand expressions in human esophageal cancer. Clin Cancer Res 1999; 5: 2464-2469.
4. Zhu Q, Liu JY, Xu HW, Yang CM, Zhang AZ, Cui Y, Wang HB. Mechanism of counterattack of colorectal cancer cell by Fas/Fas ligand system. World J Gastroenterol 2005; 11: 6125-6129.
5. Xu LN, Zou SQ, Wang JM. Action and mechanism of Fas and Fas ligand in immune escape of gallbladder carcinoma. World J Gastroenterol 2005; 11: 3719-3723.
6. Younes M, Schwartz MR, Finnie D, Younes A. Over expression of Fas ligand (FasL) during malignant transformation in the large bowel and in Barrett's metaplasia of the esophagus. Hum Pathol 1999; 30: 1309-1313.
7. Li YZ, Zhao P, Han WD. Clinicopathological significance of LRP16 protein in 336 gastric carcinoma patients. World J Gastroenterol 2009; 15: 4833-4837.
8. Bennett MW, O'connell J, O'sullivan GC, Roche D, Brady C, Kelly J, Collins JK and Shanahan F. Expression of Fas ligand by human gastric adenocarcinomas: a potential mechanism of immune escape in stomach cancer. Gut 1999; 44: 156-162.
9. Memon SA, Hou J, Moreno MB, Zacharchuk CM. Apoptosis induced by a chimeric Fas/FLICE receptor: lack of requirement for Fas-or FADD-binding proteins. J Immunol 1998; 160: 2046-2049.
10. Fukuzawa K, Takahashi K, Furuta K, Tagaya T, Ishikawa T, Wada K, Omoto Y, Koji T and Kakumu S. Expression of fas/fas ligand (fasL) and its involvement in infiltrating lymphocytes in hepatocellular carcinoma (HCC). J Gastroen-terol 2001; 36: 681-688.
11. Compagni A and Christofori G. Recent advances in research on multistage tumorigenesis. Br J Cancer 2000; 83: 1-5.
12. O'Connell J, Bennett MW, O'Sullivan GC, Collins JK and Shanahan F. The Fas counterattack: a molecular mechanism of tumor immune privilege. Mol Med 1997; 3: 294-300.
13. Takahama Y, Yamada Y, Emoto K, Fujimoto H, Takayama T, Ueno M, Uchida H, Hirao S, Mizuno T and Nakajima Y. The prognostic significance of overexpression of the decoy receptor for Fas ligand (DcR3) in patients with gastric carcinomas. Gastric Cancer 2002; 5: 61-68.
14. Yaqub S, Henjum K, Mahic M, Jahnsen FL, Aandahl EM, Bjørnbeth BA and Taskén K. Regulatory T cells in colorectal cancer patients suppress anti-tumor immune activity in a COX-2 dependent manner. Cancer Immunol Immunother 2008; 57: 813-821.
15. Lee TB, Min YD, Lim SC, Kim KJ, Jeon HJ, Choi SM and Choi CH. Fas (Apo-1/CD95) and Fas ligand interaction between gastric cancer cells and immune cells. J Gastroenterol Hepatol 2002; 17: 32-38.
16. Kume T, Oshima K, Yamashita Y, Shirakusa T and Kikuchi M. Relationship between Fas-ligand expression on carcinoma cell and cytotoxic T-lymphocyte response in lymphoepithelioma-like cancer of the stomach. Int J Cancer 1999; 84: 339-343.
17. Zhao XH, Gu SZ, Tian HG, Quan P, Pan BR. Clinical significance of expression of apoptotic signal proteins in gastric carcinoma tissue. World J Gastroenterol 2005; 11: 3846-3849.
18. Hallermalm K, De Geer A, Kiessling R, Levitsky V and Levitskaya J. Autocrine secretion of Fas ligand shields tumor cells from Fas-mediated killing by cytotoxic lymphocytes. Cancer Res 2004; 64: 6775-6782.
19. Shain KH, Landowski TH and Dalton WS. Adhesion-mediated intracellular redistribution of c-Fas-associated death domainlike IL-1-converting enzyme-like inhibitory protein-long confers resistance to CD95-induced apoptosis in hematopoietic cancer cell lines. J Immunol 2002; 168: 2544-2553.